INTERNATIONAL CORPORATE FINANCE RANKINGS
USA BEST INVESTMENT BANKS
Health & Pharma - Large Cap
The firms are listed alphabetically within each band
FIRMS KEY LEADERS
LEADING
J.P. Morgan Jeffrey Stute (Head of Healthcare Investment Banking, North America)
EXCELLENT
Barclays Jason Haas (Head of Healthcare, Americas), David Levin (Co-Head of Healthcare M&A)
Centerview Partners Kenneth Berliner (Partner, Consumer Retail and Healthcare), Stuart Smith (Parnter, Healthcare)
Citi Chris Hite (Global Head of Healthcare Investment Banking)
Goldman Sachs FX de Mallmann (Global Co-Head of Consumer Retail and Healthcare)
Morgan Stanley John Collins (Co-Head of Global Healthcare), Michele Colocci (Co-Head of Global Healthcare)
HIGHLY RECOMMENDED
Bank of America Merrill Lynch Brian Mccarthy (Vice Chairman Healthcare Investment Banking), Charles Newton (Co-Head of Healthcare)
Credit Suisse Punit Mehta (Co-Head of Healthcare Americas)
Greenhill & Co. Christopher Grubb (Co-Head of US M&A), Jeffrey Wasserstein (Managing Director, Healthcare)
Guggenheim Partners Jeffrey Hoffman (Senior Managing Director, Healthcare), Joseph Kohls (Senior Managing Director, Healthcare)
Houlihan Lokey Mark Francis (Head of Healthcare)
Lazard Jason Bernhard (Head of Healthcare Investment Banking, North America)
Track record: J.P. Morgan advised on 20 deals
in the US large-cap healthcare space for a
combined deal value of $159 billion in 2015.
Across the globe the bank has a 24% market
share in global healthcare M&A. The largest
deal advised on in this period was the sale of
US generics business of Allergen, valued at
$40.5 billion, to Teva Pharmaceutical.
Team & differentiation: J.P. Morgan’s health-
care investment banking platform offers
premium M&A expertise to both large and
small clients across healthcare services,
pharmaceuticals, biotechnology, and medi-
cal devices & life science tools. Jeffrey Stute
heads the North American Healthcare Invest-
ment Banking team.
L eader:
Jeffrey Stute
E stablished:
1823
Jeffrey Stute
J.P. MORGAN: THE LEADER IN HEALTHCARE M&A BY A WIDE MARGIN